CN107980043B - 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物 - Google Patents

多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物 Download PDF

Info

Publication number
CN107980043B
CN107980043B CN201680026195.4A CN201680026195A CN107980043B CN 107980043 B CN107980043 B CN 107980043B CN 201680026195 A CN201680026195 A CN 201680026195A CN 107980043 B CN107980043 B CN 107980043B
Authority
CN
China
Prior art keywords
polypeptide
cholesterol
nucleic acid
mammal
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680026195.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN107980043A (zh
Inventor
克莱拉·贝尔泽
威廉·迈因德特·德沃斯
帕特里斯·丹尼尔·卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gervais Danone SA
Original Assignee
Catholic University Of Luwan
Wageningen Universiteit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catholic University Of Luwan, Wageningen Universiteit filed Critical Catholic University Of Luwan
Publication of CN107980043A publication Critical patent/CN107980043A/zh
Application granted granted Critical
Publication of CN107980043B publication Critical patent/CN107980043B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201680026195.4A 2015-05-06 2016-05-04 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物 Active CN107980043B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15166598 2015-05-06
EP15166598.1 2015-05-06
PCT/EP2016/060033 WO2016177797A1 (en) 2015-05-06 2016-05-04 Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status

Publications (2)

Publication Number Publication Date
CN107980043A CN107980043A (zh) 2018-05-01
CN107980043B true CN107980043B (zh) 2021-09-24

Family

ID=74184294

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680026195.4A Active CN107980043B (zh) 2015-05-06 2016-05-04 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物

Country Status (14)

Country Link
US (2) US10738089B2 (enExample)
EP (1) EP3292135B1 (enExample)
JP (1) JP6894382B2 (enExample)
KR (1) KR102736980B1 (enExample)
CN (1) CN107980043B (enExample)
AU (2) AU2016257315A1 (enExample)
DK (1) DK3292135T3 (enExample)
EA (1) EA201700507A1 (enExample)
ES (1) ES2934138T3 (enExample)
HK (1) HK1252412A1 (enExample)
IL (1) IL255405B (enExample)
MX (1) MX390092B (enExample)
PL (1) PL3292135T3 (enExample)
WO (1) WO2016177797A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703395PA (en) 2014-10-31 2017-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
EP3292135B1 (en) 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
PL3626081T3 (pl) * 2015-09-10 2022-04-25 Université Catholique de Louvain Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych
WO2018165338A2 (en) * 2017-03-07 2018-09-13 uBiome, Inc. Therapeutic & diagnostics compositions targeting toll-like receptors and methods thereof
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
KR102340392B1 (ko) * 2018-10-08 2021-12-17 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
KR102197180B1 (ko) 2018-10-11 2020-12-31 주식회사 고바이오랩 아커만시아 뮤시니필라 균주 및 이를 포함하는 식욕 억제 및 대사성 질환 예방, 개선, 완화 및 치료용 조성물
CN110079474B (zh) * 2019-04-12 2022-11-25 沈阳药科大学 一种高密度培养艾克曼嗜黏蛋白菌的方法
KR102263030B1 (ko) * 2019-05-07 2021-06-10 한국생명공학연구원 염증성 장질환의 예방 또는 치료용 펩타이드
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
EP4079837A4 (en) * 2019-09-25 2024-06-05 HealthBiome, Inc. OBLIGATE ANAEROBIC HUMAN INTESTINAL MICROBES FOR CANCER TREATMENT AND ITS USE
KR102397916B1 (ko) * 2019-10-01 2022-05-17 (주)헬스바이옴 건강한 임산부 모유 유래 혐기성 인체 균주 및 이를 이용한 대사성 질환의 예방 또는 치료방법
CN110950937B (zh) * 2019-11-25 2021-05-04 安徽大学 一种改造的艾克曼菌Amuc_1100蛋白及其制备方法和应用
CN115315433A (zh) * 2020-01-10 2022-11-08 黄志宏 Tlr2交互作用的胜肽以及包括其的组合物
KR102671044B1 (ko) * 2020-03-25 2024-05-31 한국생명공학연구원 아커만시아 뮤시니필라 유래의 tars 또는 이의 단편 및 이의 용도
US20210322492A1 (en) * 2020-04-16 2021-10-21 Amucin Oy Ltd Probiotic strains and uses thereof
CN111690044B (zh) * 2020-05-06 2022-03-01 中南大学湘雅二医院 Amuc1100蛋白的用途
AU2021299904A1 (en) 2020-07-01 2023-01-19 Advanced Microbiome Interventions B.V. Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
WO2022098051A1 (ko) * 2020-11-05 2022-05-12 한국생명공학연구원 항염 및 조직 재생작용을 갖는 신규 펩타이드
CN113413466B (zh) * 2020-12-15 2022-08-19 和度生物医药(上海)有限公司 用于治疗癌症的amuc_1100和免疫检查点调节剂的组合疗法
CN115364198A (zh) * 2022-08-23 2022-11-22 广州康泽医疗科技有限公司 膜蛋白Amuc_1100在促进前脂肪细胞脂解和棕色化中的应用
CN116059254B (zh) * 2023-02-27 2025-04-18 广州知易生物科技有限公司 嗜黏蛋白阿克曼氏菌在制备用于改善和治疗多发性硬化症药物中的应用
KR102835266B1 (ko) 2023-09-11 2025-07-17 충남대학교산학협력단 아커만시아 뮤시니필라 m3-2 균주 및 이의 용도
CN117304264B (zh) * 2023-11-27 2024-02-06 中国科学院烟台海岸带研究所 一种具有肠屏障保护功能的五肽rp5及其应用
CN118063567B (zh) * 2024-03-03 2025-11-21 吉林大学 一种用于炎性肠病治疗的重组蛋白的制备与应用
CN119874827B (zh) * 2025-03-27 2025-06-13 杭州康源食品科技有限公司 一种具有免疫调节作用的九肽及其制备和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
NL1014380C2 (nl) 2000-02-14 2001-08-15 Friesland Brands Bv Darmwandversterkend voedingsmiddel.
US7253333B2 (en) * 2001-02-28 2007-08-07 National Institute Of Advanced Industrial Science And Technology Drosophila strain carrying bradeion gene(s) transferred thereinto
EP1583548A4 (en) * 2002-12-10 2007-10-17 Epimmune Inc HLA-A1, A2 -A3, -A24, -B7 AND B44TUMOR ASSOCIATED ANTIGENPEPTIDES AND COMPOSITIONS
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
WO2005030133A2 (en) * 2003-09-22 2005-04-07 Yale University Treatment with agonists of toll-like receptors
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
US7812121B2 (en) 2006-08-31 2010-10-12 Baker Audrey E GLP-2 mimetibodies, polypeptides, compositions, methods and uses
WO2008076696A2 (en) 2006-12-18 2008-06-26 Washington University In St. Louis The gut microbiome as a biomarker and therapeutic target for treating obesity or an obesity related disorder
EP2030623A1 (en) 2007-08-17 2009-03-04 Nestec S.A. Preventing and/or treating metabolic disorders by modulating the amount of enterobacteria
FR2944524B1 (fr) 2009-04-17 2012-11-30 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
CA2761444C (en) 2009-05-11 2018-04-24 Nestec S.A. Lactobacillus johnsonii la1 ncc533 (cncm i-1225) and immune disorders
US9104670B2 (en) 2010-07-21 2015-08-11 Apple Inc. Customized search or acquisition of digital media assets
WO2012052868A2 (en) 2010-10-20 2012-04-26 Koninklijke Philips Electronics N.V. Disaggregation apparatus
EP2449891A1 (en) 2010-11-05 2012-05-09 Nestec S.A. Drinking yoghurt preparations containing non-replicating probiotic micro-organisms
ES2565407T3 (es) 2010-11-05 2016-04-04 Nestec S.A. Procedimiento para la preparación de un producto alimenticio para animales de compañía, el cual contiene microorganismos probióticos
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
WO2014075745A1 (en) 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
KR101740893B1 (ko) * 2014-05-20 2017-06-13 주식회사 엠디헬스케어 Ａｋｋｅｒｍａｎｓｉａ ｍｕｃｉｎｉｐｈｉｌａ 균에서 유래하는 세포밖 소포를 유효성분으로 함유하는 대사질환의 치료 또는 예방용 조성물
EP3292135B1 (en) 2015-05-06 2022-09-21 Wageningen Universiteit Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
PL3626081T3 (pl) 2015-09-10 2022-04-25 Université Catholique de Louvain Pasteryzowane bakterie akkermansia w leczeniu zaburzeń metabolicznych
US11071626B2 (en) 2018-03-16 2021-07-27 W. L. Gore & Associates, Inc. Diametric expansion features for prosthetic valves

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011137369A1 (en) * 2010-04-29 2011-11-03 The Regents Of The University Of California Production of gamma-aminobutyric acid by recombinant microorganisms

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity;Amandine Everard等;《PNAS》;20130528;第110卷(第22期);第9066-9071页 *
Diabetes, obesity and gut microbiota;Amandine Everard, M.Sc.;《Best Practice & Research Clinical Gastroenterology》;20130201;第27卷(第1期);第73-83页 *
EMBL Accession:B2UR41;EMBL;《EMBL UniProtKB》;20080701;第1-4页 *
Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function;Noora Ottman等;《PLoS ONE》;20170301;第12卷(第3期);第e0173004页 *
The Genome of Akkermansia muciniphila, a Dedicated Intestinal Mucin Degrader, and Its Use in Exploring Intestinal Metagenomes;Mark W. J. van Passel等;《POLS ONE》;20110303;第6卷(第3期);第e16876页 *

Also Published As

Publication number Publication date
MX390092B (es) 2025-03-11
CN107980043A (zh) 2018-05-01
KR20180011130A (ko) 2018-01-31
EA201700507A1 (ru) 2018-05-31
AU2020267210A1 (en) 2020-12-17
ES2934138T3 (es) 2023-02-17
IL255405A0 (en) 2017-12-31
HK1252412A1 (zh) 2019-05-24
NZ737765A (en) 2024-08-30
AU2016257315A1 (en) 2017-11-23
US20180265554A1 (en) 2018-09-20
WO2016177797A1 (en) 2016-11-10
US10738089B2 (en) 2020-08-11
DK3292135T3 (da) 2022-10-31
MX2017014111A (es) 2018-02-26
AU2020267210B2 (en) 2023-10-12
PL3292135T3 (pl) 2023-01-02
KR102736980B1 (ko) 2024-12-02
JP2018515502A (ja) 2018-06-14
EP3292135B1 (en) 2022-09-21
JP6894382B2 (ja) 2021-06-30
EP3292135A1 (en) 2018-03-14
BR112017023751A2 (pt) 2018-07-31
CA2984985A1 (en) 2016-11-10
IL255405B (en) 2022-01-01
US11466057B2 (en) 2022-10-11
US20210147489A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
CN107980043B (zh) 多肽用于制备作用于免疫信号转导和/或影响肠屏障功能和/或调节代谢状态的药物
JP2018515502A5 (enExample)
JP5871911B2 (ja) 治療用ペプチドの送達のための組成物および方法
JP2022502067A (ja) アッカーマンシアムシニフィラ菌株およびその用途
KR102028771B1 (ko) 변형된 그람 양성 박테리아 및 그 사용 방법
EP4438049A1 (en) Genetically modified microorganism and use thereof
Zhang et al. Surface-displayed Amuc_1100 from Akkermansia muciniphila on Lactococcus lactis ZHY1 improves hepatic steatosis and intestinal health in high-fat-fed zebrafish
Kasarello et al. Oral administration of Lactococcus lactis expressing synthetic genes of myelin antigens in decreasing experimental autoimmune encephalomyelitis in rats
US20230265131A1 (en) Amuc-1100 polypeptide variants for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
US20230172997A1 (en) Recombinant bacteria for production of indole-3-acetic acid (iaa) and uses thereof
JP6629955B2 (ja) 減量脂質低下のための形質転換体およびその構築方法、並びにその応用
CA2984985C (en) Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status
CN102181437B (zh) 猪脂联素球状结构域蛋白gAd基因及其编码的蛋白和应用
EA040421B1 (ru) Композиция, клетки, способы получения полипептида, применение полипептида и клеток, способ лечения
BR112017023751B1 (pt) Uso de um polipeptídeo para efetuar a sinalização imune e/ou afetar a função de barreira intestinal e/ou condição metabólica modular
Vivekanandan et al. Overview of cloning in lactic acid bacteria: Expression and its application of probiotic potential in inflammatory bowel diseases
CN109679964A (zh) 一种表达人胰岛素基因的重组乳酸乳球菌
WO2019036859A1 (zh) 分泌glp-1及其衍生物的蛋白表达系统及其制备方法和用途
RU2773435C2 (ru) Модифицированные грамположительные бактерии и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250707

Address after: Provincial Road 91190, 128 Giff sur Yvette, France

Patentee after: COMPAGNIE GERVAIS DANONE

Country or region after: France

Address before: Wageningen

Patentee before: WAGENINGEN UNIVERSITEIT

Country or region before: Netherlands

Patentee before: UNIVERSITE CATHOLIQUE DE LOUVAIN

Country or region before: Belgium